https://ir.scynexis.com/ https://ir.scynexis.com/news https://ir.scynexis.com/events-presentations https://ir.scynexis.com/financials/financial-results https://ir.scynexis.com/financials/sec-filings https://ir.scynexis.com/financials/annual-reports https://ir.scynexis.com/financials/quarterly-reports https://ir.scynexis.com/stock-info/quote https://ir.scynexis.com/stock-info/historical-data https://ir.scynexis.com/stock-info/analyst-coverage https://ir.scynexis.com/governance https://ir.scynexis.com/governance/board-of-directors https://ir.scynexis.com/governance/governance-documents https://ir.scynexis.com/resources/faq https://ir.scynexis.com/resources/contacts https://ir.scynexis.com/resources/email-alerts https://ir.scynexis.com/news/detail/374/scynexis-to-feature-scy-247-in-a-pipeline-presentation-at-idweek 2026-10-21T16:05:03-04:00 https://ir.scynexis.com/news/detail/373/scynexis-announces-phase-1-study-results-for-scy-770-a-novel-highly-selective-oral-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd 2026-10-06T07:30:02-04:00 https://ir.scynexis.com/news/detail/372/scynexis-awarded-barda-contract-providing-up-to-214-million-in-non-dilutive-funding-for-the-development-of-scy-247 2026-09-28T08:08:02-04:00 https://ir.scynexis.com/news/detail/371/scynexis-appoints-seasoned-industry-veteran-steven-k-burke-m-d-to-its-board-of-directors 2026-09-22T08:00:09-04:00 https://ir.scynexis.com/news/detail/370/scynexis-appoints-todd-minga-m-d-as-senior-vice-president-research-development 2026-09-15T08:00:11-04:00 https://ir.scynexis.com/news/detail/369/scynexis-announces-appointment-of-sanjay-subramanian-as-chief-financial-officer 2026-09-10T08:00:11-04:00 https://ir.scynexis.com/news/detail/368/scynexis-to-participate-in-upcoming-investor-conferences 2026-09-01T08:30:02-04:00 https://ir.scynexis.com/news/detail/367/scynexis-announces-inducement-award-under-nasdaq-listing-rule-5635c4 2026-08-25T19:06:47-04:00 https://ir.scynexis.com/news/detail/366/scynexis-reports-second-quarter-2026-financial-results-and-provides-corporate-update 2026-08-10T16:30:02-04:00 https://ir.scynexis.com/news/detail/365/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd 2026-06-30T08:00:27-04:00 https://ir.scynexis.com/news/detail/364/scynexis-announces-one-for-eight-reverse-stock-split 2026-05-22T16:15:01-04:00 https://ir.scynexis.com/news/detail/363/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update 2026-05-11T16:23:31-04:00 https://ir.scynexis.com/news/detail/362/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635c4 2026-05-06T21:15:29-04:00 https://ir.scynexis.com/news/detail/361/scynexis-announces-40-0-million-private-placement 2026-03-31T06:45:01-04:00 https://ir.scynexis.com/news/detail/360/scynexis-completes-transformative-acquisition-of-pxl-770-an-innovative-highly-selective-direct-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd 2026-03-31T06:40:01-04:00 https://ir.scynexis.com/news/detail/359/scynexis-reports-full-year-2025-financial-results-and-provides-corporate-update 2026-03-04T16:20:01-05:00 https://ir.scynexis.com/news/detail/358/scynexis-announces-first-participants-dosed-in-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-trial-of-intravenous-scy-247 2026-02-26T08:23:30-05:00 https://ir.scynexis.com/news/detail/357/scynexis-announces-presentations-highlighting-the-potent-antifungal-activity-of-its-second-generation-fungerp-scy-247-against-drug-resistant-fungi-atthe-inaugural-interdisciplinary-meeting-on-antimicrobial-resistance-and-innovation-imari 2026-01-28T08:00:13-05:00 https://ir.scynexis.com/news/detail/356/scynexis-receives-fda-qualified-infectious-disease-product-qidp-and-fast-track-designations-for-scy-247 2026-01-21T08:00:06-05:00 https://ir.scynexis.com/news/detail/355/scynexis-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement 2025-12-22T08:00:04-05:00 https://ir.scynexis.com/news/detail/354/scynexis-completes-transfer-of-brexafemme-new-drug-application-to-gsk 2025-11-19T07:00:01-05:00 https://ir.scynexis.com/news/detail/353/scynexis-announces-federal-funding-of-collaboration-between-hackensack-meridian-cdi-and-johns-hopkins-researchers-to-develop-new-therapeutics-including-novel-fungerps-for-resistant-fungal-infections 2025-11-17T10:15:01-05:00 https://ir.scynexis.com/news/detail/352/scynexis-reports-third-quarter-2025-financial-results-and-provides-corporate-update 2025-11-05T16:20:02-05:00 https://ir.scynexis.com/news/detail/351/scynexis-and-gsk-resolve-their-disagreement-related-to-the-restart-of-the-phase-3-mario-study 2025-10-15T08:00:11-04:00 https://ir.scynexis.com/news/detail/350/scynexis-announces-positive-results-from-a-phase-1-single-ascending-dose-and-multiple-ascending-dose-study-of-its-second-generation-fungerp-scy-247 2025-09-30T08:00:06-04:00 https://ir.scynexis.com/news/detail/349/scynexis-announces-multiple-presentations-highlighting-data-from-its-second-generation-fungerp-scy-247-at-the-12th-congress-on-trends-in-medical-mycology-timm-12 2025-09-04T08:30:02-04:00 https://ir.scynexis.com/news/detail/348/scynexis-to-participate-in-the-h-c-wainwright-27th-annual-global-conference-september-8-10-2025 2025-08-25T08:00:16-04:00 https://ir.scynexis.com/news/detail/347/scynexis-reports-second-quarter-2025-financial-resultsand-provides-corporate-update 2025-08-13T16:30:04-04:00 https://ir.scynexis.com/news/detail/346/scynexis-resumes-patient-dosing-in-phase-3-mario-study 2025-05-28T08:30:04-04:00 https://ir.scynexis.com/news/detail/345/scynexis-reports-first-quarter-2025-financial-resultsand-provides-corporate-update 2025-05-15T16:20:01-04:00 https://ir.scynexis.com/news/detail/344/scynexis-to-present-preclinical-data-on-second-generation-ivoral-fungerp-scy-247-at-the-european-society-of-clinical-microbiology-and-infectious-diseases-escmid 2025-04-08T08:00:10-04:00 https://ir.scynexis.com/news/detail/343/scynexis-reports-full-year-2024-financial-resultsand-provides-corporate-update 2025-03-12T17:08:58-04:00 https://ir.scynexis.com/news/detail/342/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-a-second-generation-fungerp-candidate-for-invasive-fungal-infections 2024-12-18T08:00:10-05:00 https://ir.scynexis.com/news/detail/341/scynexis-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-06T16:30:14-05:00 https://ir.scynexis.com/news/detail/340/scynexis-to-participate-in-the-2024-maxim-healthcare-virtual-summit 2024-10-10T08:00:13-04:00 https://ir.scynexis.com/news/detail/339/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-idweek-2024 2024-10-03T08:00:07-04:00 https://ir.scynexis.com/news/detail/338/scynexis-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference 2024-08-27T08:00:03-04:00 https://ir.scynexis.com/news/detail/337/scynexis-reports-second-quarter-2024-financial-resultsand-provides-corporate-update 2024-08-08T16:30:02-04:00 https://ir.scynexis.com/news/detail/336/scynexis-to-receive-10-million-milestone-payment-from-gsk-triggered-by-delivery-of-completed-furi-cares-and-nature-clinical-study-reports 2024-07-23T07:00:03-04:00 https://ir.scynexis.com/news/detail/335/scynexis-reports-first-quarter-2024-financial-resultsand-provides-corporate-update 2024-05-08T16:30:02-04:00 https://ir.scynexis.com/news/detail/334/scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-247-at-the-congress-of-the-european-society-of-clinical-microbiology-and-infectious-diseases-escmid-global-formerly-eccmid 2024-04-30T16:05:15-04:00 https://ir.scynexis.com/news/detail/333/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-34th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid 2024-04-09T16:05:04-04:00 https://ir.scynexis.com/news/detail/332/scynexis-reports-full-year-2023-financial-resultsand-provides-corporate-update 2024-03-28T16:01:04-04:00 https://ir.scynexis.com/news/detail/331/scynexis-to-participate-in-guggenheims-6th-annual-biotechnology-conference 2024-01-30T16:05:01-05:00 https://ir.scynexis.com/news/detail/330/scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-247-against-mucormycosis-at-the-11th-advances-against-aspergillosis-and-mucormycosis-conference 2024-01-29T17:15:11-05:00 https://ir.scynexis.com/news/detail/329/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-advances-against-aspergillosis-and-mucormycosis-conference-january-25-27-in-milan-italy 2024-01-05T08:30:15-05:00 https://ir.scynexis.com/news/detail/328/scynexis-reports-third-quarter-2023-financial-results-and-provides-corporate-update 2023-11-13T17:17:43-05:00 https://ir.scynexis.com/news/detail/327/scynexis-presents-new-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-congress-on-trends-in-medical-mycology-timm 2023-10-24T08:00:01-04:00 https://ir.scynexis.com/news/detail/326/scynexis-to-present-preclinical-data-on-second-generation-fungerp-scy-247-at-the-11th-congress-on-trends-in-medical-mycology-timm-october-20-23-in-athens-greece 2023-10-16T08:00:02-04:00 https://ir.scynexis.com/news/detail/325/scynexis-issues-a-voluntary-nationwide-recall-of-brexafemme-ibrexafungerp-tablets-due-to-potential-for-cross-contamination-with-a-non-antibacterial--lactam-drug-substance 2023-09-27T20:31:06-04:00 https://ir.scynexis.com/news/detail/324/scynexis-to-participate-in-september-investor-conferences 2023-08-28T08:00:04-04:00 https://ir.scynexis.com/news/detail/323/scynexis-reports-second-quarter-2023-financial-results-and-provides-corporate-update 2023-08-14T16:30:03-04:00 https://ir.scynexis.com/news/detail/322/scynexis-and-hansoh-pharma-announce-nmpa-acceptance-of-the-new-drug-application-for-ibrexafungerp-in-china 2023-07-20T09:58:29-04:00 https://ir.scynexis.com/news/detail/321/scynexis-announces-achievement-of-first-development-milestone-of-25-million-under-exclusive-license-agreement-with-gsk 2023-06-21T07:00:04-04:00 https://ir.scynexis.com/news/detail/320/scynexis-to-participate-in-the-maxim-group-virtual-healthcare-conference 2023-06-15T16:10:01-04:00 https://ir.scynexis.com/news/detail/319/scynexis-reports-closing-of-exclusive-license-agreement-with-gsk-forbrexafemme-ibrexafungerp-tablets 2023-05-12T08:00:07-04:00 https://ir.scynexis.com/news/detail/318/scynexis-announces-first-quarter-2023-financial-results-and-provides-corporate-update 2023-05-11T07:00:29-04:00 https://ir.scynexis.com/news/detail/317/scynexis-to-present-ibrexafungerp-data-at-the-33rd-annual-european-congress-of-clinical-microbiology-infectious-diseases-eccmid-april-15-18-in-denmark 2023-04-13T08:30:06-04:00 https://ir.scynexis.com/news/detail/316/scynexis-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update 2023-03-31T08:30:04-04:00 https://ir.scynexis.com/news/detail/315/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp-a-novel-first-in-class-medicine-to-treat-fungal-infection 2023-03-30T07:05:02-04:00 https://ir.scynexis.com/news/detail/314/scynexis-announces-fda-approval-of-second-indication-for-brexafemme-ibrexafungerp-tablets-for-reduction-in-incidence-of-recurrent-vulvovaginal-candidiasis 2022-12-01T08:00:06-05:00 https://ir.scynexis.com/news/detail/313/scynexis-announces-3-million-national-institutes-of-health-grant-has-been-awarded-to-case-western-reserve-university-researchers-to-study-second-generation-fungerp-scy-247-to-fight-drug-resistant-fungi 2022-11-30T08:30:02-05:00 https://ir.scynexis.com/news/detail/312/scynexis-applauds-the-biomedical-advanced-research-and-development-authority-barda-for-its-new-priority-focus-on-investment-in-development-of-antifungal-treatments-to-fight-infections-caused-by-drug-resistant-fungal-threats 2022-11-17T08:30:05-05:00 https://ir.scynexis.com/news/detail/311/scynexis-reports-third-quarter-2022-financial-resultsand-provides-corporate-update 2022-11-09T07:00:08-05:00 https://ir.scynexis.com/news/detail/310/scynexis-announces-publication-of-review-article-highlighting-ibrexafungerp-as-a-potential-novel-treatment-for-invasive-mold-infections-in-the-journal-of-fungi 2022-11-07T08:30:03-05:00 https://ir.scynexis.com/news/detail/309/pooled-data-from-the-pivotal-phase-3-vanish-program-published-in-the-journal-of-womens-health-demonstrate-significant-efficacy-of-ibrexafungerp-over-placebo-for-treatment-of-vaginal-yeast-infection 2022-11-03T08:30:01-04:00 https://ir.scynexis.com/news/detail/308/scynexis-to-report-third-quarter-2022-financial-results-and-provide-a-corporate-update-on-november-9 2022-11-01T08:30:01-04:00 https://ir.scynexis.com/news/detail/307/biopharma-veteran-ivor-macleod-joins-scynexis-as-chief-financial-officer 2022-10-25T08:30:01-04:00 https://ir.scynexis.com/news/detail/306/scynexis-presents-positive-interim-data-of-oral-ibrexafungerp-for-severe-fungal-infections-from-ongoing-phase-3-furi-study-during-idweek-2022 2022-10-24T08:30:04-04:00 https://ir.scynexis.com/news/detail/305/scynexis-provides-corporate-commercial-and-rd-strategy-updates-to-expand-market-potential-for-its-first-in-class-antifungal 2022-10-20T07:00:03-04:00 https://ir.scynexis.com/news/detail/304/scynexis-to-present-positive-interim-data-from-the-phase-3-furi-study-of-oral-ibrexafungerp-at-idweek-2022 2022-10-11T08:30:04-04:00 https://ir.scynexis.com/news/detail/303/scynexis-to-participate-in-upcoming-september-investor-conferences 2022-09-09T08:30:05-04:00 https://ir.scynexis.com/news/detail/302/scynexis-presents-positive-interim-data-of-ibrexafungerp-for-refractory-candida-infections-from-ongoing-phase-3-furi-study-during-the-mycoses-study-group-education-and-research-consortium-msgerc-biennial-meeting 2022-09-08T08:30:02-04:00 https://ir.scynexis.com/news/detail/301/scynexis-to-present-posters-highlighting-ibrexafungerp-data-at-four-upcoming-scientific-meetings-in-september-2022 2022-09-01T08:30:04-04:00 https://ir.scynexis.com/news/detail/300/scynexis-reports-second-quarter-2022-financial-results-and-provides-corporate-update 2022-08-15T15:34:31-04:00 https://ir.scynexis.com/news/detail/299/scynexis-to-report-second-quarter-2022-financial-results-and-provide-a-corporate-update-on-august-15 2022-08-09T08:30:10-04:00 https://ir.scynexis.com/news/detail/298/scynexis-presents-positive-data-from-its-pivotal-phase-3-candle-study-of-oral-ibrexafungerp-for-prevention-of-recurrent-vaginal-yeast-infections-during-the-2022-idsog-annual-meeting 2022-08-04T08:30:07-04:00 https://ir.scynexis.com/news/detail/297/scynexis-announces-u-s-food-and-drug-administration-acceptance-and-priority-review-of-the-supplemental-new-drug-application-for-brexafemme-ibrexafungerp-tablets-for-prevention-of-recurrent-vaginal-yeast-infections 2022-08-01T08:30:05-04:00 https://ir.scynexis.com/news/detail/296/scynexis-presents-positive-data-from-phase-3-candle-nested-sub-study-investigating-ibrexafungerp-in-women-with-recurrent-yeast-infections-who-failed-fluconazole-during-the-issvd-xxvi-world-congress-and-international-vulvovaginal-disease-update 2022-07-19T08:35:30-04:00 https://ir.scynexis.com/news/detail/295/scynexis-to-present-data-from-the-candle-nested-sub-study-of-ibrexafungerp-during-the-international-society-for-the-study-of-vulvovaginal-disease-issvd-xxvi-world-congress-and-international-vulvovaginal-disease-update 2022-07-14T08:30:03-04:00 https://ir.scynexis.com/news/detail/294/scynexis-announces-initiation-of-new-phase-3b-study-vanquish-to-evaluate-oral-ibrexafungerp-as-a-treatment-for-complicated-vulvovaginal-candidiasis-vvc-in-patients-who-failed-to-respond-to-treatment-with-fluconazole 2022-06-23T08:30:05-04:00 https://ir.scynexis.com/news/detail/293/scynexis-announces-submission-of-supplemental-new-drug-application-of-ibrexafungerp-to-the-u-s-food-and-drug-administration-for-an-expanded-indication-for-the-prevention-of-recurrent-vaginal-yeast-infections 2022-06-22T13:56:56-04:00 https://ir.scynexis.com/news/detail/292/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-06-03T16:05:02-04:00 https://ir.scynexis.com/news/detail/291/scynexis-to-present-at-upcoming-h-c-wainwright-global-investment-conference 2022-05-20T08:30:04-04:00 https://ir.scynexis.com/news/detail/290/scynexis-reports-first-quarter-2022-financial-resultsand-provides-corporate-update 2022-05-12T07:00:20-04:00 https://ir.scynexis.com/news/detail/289/scynexis-presents-new-interim-positive-data-of-ibrexafungerp-for-refractory-vulvovaginal-candidiasis-from-ongoing-phase-3-furi-study-at-the-american-college-of-obstetricians-and-gynecologists-acog-annual-clinical-scientific-meeting 2022-05-10T08:30:05-04:00 https://ir.scynexis.com/news/detail/288/scynexis-to-report-first-quarter-2022-financial-results-and-provide-a-corporate-update-on-may-12 2022-05-05T08:30:05-04:00 https://ir.scynexis.com/news/detail/287/scynexis-to-present-new-data-of-ibrexafungerp-for-refractory-vulvovaginal-candidiasis-from-ongoing-phase-3-furi-study-at-the-american-college-of-obstetricians-and-gynecologists-acog-annual-clinical-scientific-meeting 2022-05-04T08:30:07-04:00 https://ir.scynexis.com/news/detail/286/scynexis-presents-data-analyses-showing-ibrexafungerps-potential-to-fight-invasive-candidiasis-and-candidemia-including-infections-caused-by-candida-auris-during-the-32nd-annual-european-congress-of-clinical-microbiology-infectious-diseases 2022-04-27T08:30:03-04:00 https://ir.scynexis.com/news/detail/285/scynexis-announces-closing-of-45-million-public-offering-of-common-stock-pre-funded-warrants-and-warrants 2022-04-26T17:18:01-04:00 https://ir.scynexis.com/news/detail/284/scynexis-announces-pricing-of-45-million-public-offering-of-common-stock-pre-funded-warrants-and-warrants 2022-04-22T08:15:40-04:00 https://ir.scynexis.com/news/detail/283/scynexis-announces-positive-interim-data-from-phase-3-furi-and-cares-studies-highlighting-oral-ibrexafungerps-potency-against-severe-fungal-infections 2022-04-22T08:00:04-04:00 https://ir.scynexis.com/news/detail/282/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants 2022-04-21T16:01:01-04:00 https://ir.scynexis.com/news/detail/281/scynexis-to-present-positive-interim-data-from-ongoing-furi-and-cares-studies-at-the-32nd-annual-european-congress-of-clinical-microbiology-infectious-diseases-eccmid-being-held-april-23-26-in-lisbon-portugal 2022-04-20T08:30:04-04:00 https://ir.scynexis.com/news/detail/280/scynexis-secures-additional-commercial-insurance-formulary-coverage-for-brexafemme-ibrexafungerp-tablets-providing-access-to-an-estimated-93-million-commercially-insured-lives 2022-04-19T08:30:06-04:00 https://ir.scynexis.com/news/detail/279/scynexis-to-participate-in-upcoming-april-womens-health-medical-conferences 2022-04-04T09:59:05-04:00 https://ir.scynexis.com/news/detail/278/scynexis-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-corporate-update 2022-03-29T08:00:39-04:00 https://ir.scynexis.com/news/detail/277/scynexis-to-report-fourth-quarter-and-full-year-2021-financial-results-andprovide-a-business-update 2022-03-24T08:30:05-04:00 https://ir.scynexis.com/news/detail/276/scynexis-named-to-fast-companys-2022-list-of-the-worlds-most-innovative-companies 2022-03-08T10:00:51-05:00 https://ir.scynexis.com/news/detail/275/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-03-04T17:00:02-05:00 https://ir.scynexis.com/news/detail/274/scynexis-to-participate-in-upcoming-scientific-conferences-and-events 2022-03-02T08:30:07-05:00 https://ir.scynexis.com/news/detail/273/scynexis-announces-positive-results-from-its-pivotal-phase-3-candle-study-of-oral-ibrexafungerp-for-prevention-of-recurrent-vaginal-yeast-infections-clearing-the-way-for-regulatory-submission-and-potential-approval-of-additional-indication-by-end-of-2022 2022-02-10T07:36:34-05:00 https://ir.scynexis.com/news/detail/272/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-02-03T16:15:03-05:00 https://ir.scynexis.com/news/detail/271/scynexis-to-participate-in-upcoming-january-investor-conferences 2022-01-06T13:03:13-05:00 https://ir.scynexis.com/news/detail/270/scynexis-reports-the-exercise-of-warrants-totalling-21-1-million 2021-12-22T08:30:03-05:00 https://ir.scynexis.com/news/detail/269/brexafemme-ibrexafungerp-tablets-added-to-major-national-formulary-providing-access-for-millions-more-commercially-insured-patients 2021-12-20T08:30:03-05:00 https://ir.scynexis.com/news/detail/268/european-medicines-agency-grants-orphan-medicinal-product-designation-for-scynexis-innovative-antifungal-ibrexafungerp-for-the-indication-of-invasive-candidiasis 2021-12-15T08:30:04-05:00 https://ir.scynexis.com/news/detail/267/scynexis-announces-agreement-with-fda-on-innovative-strategy-for-approval-of-oral-ibrexafungerp-for-treatment-of-invasive-candidiasis 2021-12-06T07:00:04-05:00 https://ir.scynexis.com/news/detail/266/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2021-12-03T16:30:01-05:00 https://ir.scynexis.com/news/detail/265/scynexis-reports-the-exercise-of-warrants-totalling-7-9-million 2021-12-03T08:43:33-05:00 https://ir.scynexis.com/news/detail/264/brexafemme-ibrexafungerp-tablets-receives-2021-popular-science-best-of-whats-new-award-in-the-health-category 2021-12-01T10:37:28-05:00 https://ir.scynexis.com/news/detail/263/scynexis-to-host-ibrexafungerp-hospital-pipeline-update-call-and-kol-webcast-for-investors-on-december-6 2021-11-29T08:30:02-05:00 https://ir.scynexis.com/news/detail/262/scynexis-pivotal-phase-3-vanish-306-trial-results-published-in-the-international-journal-of-obstetrics-and-gynaecology-bjog-demonstrate-statistical-superiority-of-brexafemmeibrexafungerp-tablets-over-placebo-for-vaginal-yeast-infection 2021-11-23T08:30:03-05:00 https://ir.scynexis.com/news/detail/261/scynexis-reports-third-quarter-2021-financial-results-and-provides-corporate-update 2021-11-10T07:34:01-05:00 https://ir.scynexis.com/news/detail/260/scynexis-announces-successful-completion-of-phase-1-trial-evaluatingintravenous-iv-formulation-of-ibrexafungerp 2021-11-09T08:30:03-05:00 https://ir.scynexis.com/news/detail/259/scynexis-to-provide-a-corporate-update-and-report-third-quarter-2021financial-results-on-november-10 2021-11-03T08:30:02-04:00 https://ir.scynexis.com/news/detail/258/scynexis-pivotal-phase-3-vanish-303-trial-results-published-in-clinical-infectious-diseases-demonstrate-significant-superiority-of-ibrexafungerp-over-placebo-for-treatment-of-vaginal-yeast-infection 2021-10-21T08:30:05-04:00 https://ir.scynexis.com/news/detail/257/scynexis-to-present-pooled-data-analysis-results-demonstrating-consistent-efficacy-and-safety-outcomes-across-two-phase-3-vanish-clinical-trials-of-oral-ibrexafungerp-therapy-for-vaginal-yeast-infection-at-october-medical-conferences 2021-10-13T08:30:04-04:00 https://ir.scynexis.com/news/detail/256/scynexis-announces-preclinical-data-at-the-10th-trends-in-medical-mycology-meeting-supporting-potential-of-ibrexafungerp-to-treat-mucormycosis 2021-10-11T08:30:04-04:00 https://ir.scynexis.com/news/detail/255/scynexis-to-present-clinical-data-from-ongoing-furi-and-cares-studies-at-the-10th-trends-in-medical-mycology-meeting-showing-oral-ibrexafungerp-provides-a-favorable-therapeutic-response-in-patients-with-severe-fungal-infections 2021-10-07T08:00:05-04:00 https://ir.scynexis.com/news/detail/254/scynexis-presents-interim-analysis-from-furi-at-virtual-idweek-2021-showing-favorable-therapeutic-response-in-severe-hospital-based-fungal-infections-treated-with-oral-ibrexafungerp 2021-09-30T15:35:45-04:00 https://ir.scynexis.com/news/detail/253/scynexis-to-present-data-on-oral-ibrexafungerp-at-idweek-2021-from-interim-analyses-of-phase-3-furi-clinical-trial-showing-therapeutic-response-rates-in-patients-with-mucocutaneous-and-invasive-fungal-infections 2021-09-23T08:30:01-04:00 https://ir.scynexis.com/news/detail/252/scynexis-announces-u-s-availability-of-brexafemme-ibrexafungerp-tablets-the-first-new-antifungal-class-of-therapy-approved-by-the-u-s-fda-for-vaginal-yeast-infections-in-more-than-20-years 2021-09-22T08:30:08-04:00 https://ir.scynexis.com/news/detail/251/scynexis-announces-hansoh-pharmas-application-to-national-medical-products-administration-nmpa-in-china-for-phase-3-trial-of-ibrexafungerp-for-treatment-of-vulvovaginal-candidiasis-vvc 2021-09-13T08:30:05-04:00 https://ir.scynexis.com/news/detail/250/scynexis-to-participate-in-upcoming-investor-conferences 2021-09-08T08:30:16-04:00 https://ir.scynexis.com/news/detail/249/scynexis-reports-second-quarter-2021-financial-results-and-provides-corporate-update 2021-08-16T08:00:12-04:00 https://ir.scynexis.com/news/detail/248/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2021-08-02T17:00:01-04:00 https://ir.scynexis.com/news/detail/247/scynexis-announces-two-oral-presentations-on-pooled-data-from-the-brexafemme-ibrexafungerp-tablets-phase-3-vanish-program-demonstrating-consistent-efficacy-in-the-treatment-for-vaginal-yeast-infections-at-the-idsog-2021-virtual-annual-meeting 2021-07-29T08:00:07-04:00 https://ir.scynexis.com/news/detail/246/scynexis-announces-three-oral-presentations-of-ibrexafungerp-demonstrating-clinical-and-in-vitro-activity-against-candida-species-at-the-31st-eccmid 2021-07-12T08:00:02-04:00 https://ir.scynexis.com/news/detail/245/scynexis-to-present-at-ladenburg-thalmanns-virtual-2021-healthcare-conference 2021-07-07T08:30:04-04:00 https://ir.scynexis.com/news/detail/244/scynexis-reports-inducement-grants-under-nasdaq-listing-rule-5635c4 2021-07-02T16:01:02-04:00 https://ir.scynexis.com/news/detail/243/scynexis-to-present-commercial-launch-update-for-brexafemme-ibrexafungerp-tablets 2021-06-23T08:30:05-04:00 https://ir.scynexis.com/news/detail/242/scynexis-to-present-at-the-bio-digital-international-convention-2021 2021-06-11T08:30:01-04:00 https://ir.scynexis.com/news/detail/241/scynexis-confirms-that-brexafemme-ibrexafungerp-tablets-qualifies-for-10-years-of-regulatory-exclusivity-for-vaginal-yeast-infections 2021-06-09T08:30:04-04:00 https://ir.scynexis.com/news/detail/240/scynexis-announces-fda-approval-of-brexafemme-ibrexafungerp-tablets-as-the-first-and-only-oral-non-azole-treatment-for-vaginal-yeast-infections 2021-06-02T07:30:03-04:00 https://ir.scynexis.com/news/detail/239/scynexis-reports-first-quarter-2021-financial-results-and-provides-corporate-update 2021-05-17T08:30:05-04:00 https://ir.scynexis.com/news/detail/238/scynexis-secures-term-loan-facility-for-up-to-60-million-with-hercules-capital-and-silicon-valley-bank 2021-05-14T08:30:07-04:00 https://ir.scynexis.com/news/detail/237/scynexis-appoints-accomplished-commercial-executive-christine-coyne-as-chief-commercial-officer-to-lead-the-brexafemme-launch 2021-05-11T08:30:05-04:00 https://ir.scynexis.com/news/detail/236/scynexis-presents-data-at-2021-acog-demonstrating-the-positive-outcome-and-sustained-response-of-investigational-oral-ibrexafungerp-brexafemme-in-difficult-to-treat-patients-with-vaginal-yeast-infections 2021-04-30T08:00:02-04:00 https://ir.scynexis.com/news/detail/235/scynexis-to-present-two-ibrexafungerp-brexafemme-posters-at-the-2021-american-college-of-obstetricians-and-gynecologists-acog-annual-clinical-and-scientific-meeting 2021-04-20T08:00:09-04:00 https://ir.scynexis.com/news/detail/234/scynexis-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides-corporate-update 2021-03-29T08:20:01-04:00 https://ir.scynexis.com/news/detail/233/scynexis-announces-positive-results-from-interim-analyses-of-ongoing-phase-3-studies-furi-and-cares-demonstrating-oral-ibrexafungerps-ability-to-treat-severe-fungal-infections-in-the-hospital-setting 2021-03-02T07:30:03-05:00 https://ir.scynexis.com/news/detail/232/scynexis-to-participate-in-maxim-groups-late-stage-innovations-in-womens-health-virtual-event 2021-02-25T16:15:03-05:00 https://ir.scynexis.com/news/detail/231/scynexis-and-amplity-health-announce-agreement-to-support-the-anticipated-u-s-commercialization-of-brexafemmetm-ibrexafungerp-for-vaginal-yeast-infections 2021-02-23T08:15:00-05:00 https://ir.scynexis.com/news/detail/230/scynexis-announces-licensing-agreement-and-strategic-partnership-with-hansoh-pharma-for-rights-to-ibrexafungerp-in-greater-china 2021-02-17T08:15:01-05:00 https://ir.scynexis.com/news/detail/229/scynexis-announces-closing-of-85-million-public-offering-of-common-stock-pre-funded-warrants-and-warrants 2020-12-22T08:00:02-05:00 https://ir.scynexis.com/news/detail/228/scynexis-announces-pricing-of-85-million-public-offering-of-common-stock-pre-funded-warrants-and-warrants 2020-12-17T09:28:48-05:00 https://ir.scynexis.com/news/detail/227/scynexis-announces-launch-of-50-million-public-offering-of-common-stock-and-warrants 2020-12-16T16:21:20-05:00 https://ir.scynexis.com/news/detail/226/scynexis-announces-advancement-of-ibrexafungerps-intravenous-formulation-to-clinical-stage-and-provides-further-updates-on-its-clinical-studies-in-patients-with-life-threatening-fungal-infections 2020-12-10T08:00:01-05:00 https://ir.scynexis.com/news/detail/225/scynexis-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-oral-ibrexafungerp-for-the-treatment-of-vaginal-yeast-infections 2020-12-07T08:00:03-05:00 https://ir.scynexis.com/news/detail/224/scynexis-to-participate-in-piper-sandler-and-evercore-isi-conferences 2020-11-24T09:35:03-05:00 https://ir.scynexis.com/news/detail/223/scynexis-reports-third-quarter-2020-financial-results-and-provides-company-update 2020-11-06T08:44:40-05:00 https://ir.scynexis.com/news/detail/222/scynexis-to-present-data-supporting-the-efficacy-of-ibrexafungerp-against-invasive-fungal-infections-at-idweek-2020 2020-10-21T08:30:04-04:00 https://ir.scynexis.com/news/detail/221/scynexis-announces-submission-of-new-drug-application-to-the-u-s-food-and-drug-administration-for-oral-ibrexafungerp-for-the-treatment-of-vaginal-yeast-infection 2020-10-14T08:30:08-04:00 https://ir.scynexis.com/news/detail/220/scynexis-to-present-two-posters-highlighting-ibrexafungerp-for-the-treatment-of-vaginal-yeast-infection-at-the-23rd-annual-premier-womens-healthcare-virtual-conference 2020-10-12T08:30:04-04:00 https://ir.scynexis.com/news/detail/219/scynexis-to-participate-in-h-c-wainwright-conference-and-maxims-antifungal-webinar 2020-09-10T08:38:08-04:00 https://ir.scynexis.com/news/detail/218/scynexis-announces-presentations-at-2020-idsog-virtual-annual-meeting-highlighting-ibrexafungerps-potential-for-the-treatment-of-vulvovaginal-candidiasis 2020-08-13T08:00:08-04:00 https://ir.scynexis.com/news/detail/217/scynexis-reports-second-quarter-2020-financial-results-and-provides-company-update 2020-08-10T08:20:03-04:00 https://ir.scynexis.com/news/detail/216/scynexis-reports-successful-completion-of-pre-nda-meetings-with-the-fda-regarding-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis 2020-07-29T08:00:09-04:00 https://ir.scynexis.com/news/detail/215/scynexis-announces-four-posters-presented-at-asm-microbe-2020-highlighting-the-potential-clinical-utility-of-ibrexafungerp 2020-07-22T07:59:49-04:00 https://ir.scynexis.com/news/detail/214/scynexis-announces-one-for-ten-reverse-stock-split 2020-07-16T09:00:11-04:00 https://ir.scynexis.com/news/detail/213/scynexis-to-host-a-key-opinion-leader-discussion-on-the-immediate-need-in-treating-women-with-vaginal-yeast-infections 2020-07-09T08:00:10-04:00 https://ir.scynexis.com/news/detail/212/scynexis-to-present-at-the-bio-digital-international-convention-2020 2020-06-08T09:50:41-04:00 https://ir.scynexis.com/news/detail/211/scynexis-strengthens-leadership-team-with-appointment-of-jim-maffezzoli-as-vice-president-of-marketing-and-sales 2020-06-02T08:00:14-04:00 https://ir.scynexis.com/news/detail/210/scynexis-reports-first-quarter-2020-financial-results-and-provides-company-update 2020-05-11T08:50:02-04:00 https://ir.scynexis.com/news/detail/209/scynexis-announces-six-abstracts-published-by-30th-eccmid-highlighting-the-potential-clinical-utility-of-ibrexafungerp 2020-05-06T08:00:10-04:00 https://ir.scynexis.com/news/detail/208/scynexis-to-participate-in-antifungals-panel-at-maxim-groups-infectious-disease-virtual-conference-the-renaissance-of-the-anti-infective-sector 2020-04-28T08:00:14-04:00 https://ir.scynexis.com/news/detail/207/scynexis-announces-positive-top-line-results-from-its-second-pivotal-phase-3-study-vanish-306-of-oral-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vaginal-yeast-infection 2020-04-21T07:00:12-04:00 https://ir.scynexis.com/news/detail/206/scynexis-and-aspire-capital-enter-into-20-million-common-stock-purchase-agreement 2020-04-13T08:54:32-04:00 https://ir.scynexis.com/news/detail/205/scynexis-secures-10-million-in-financing-through-senior-convertible-note-purchase-agreement-with-puissance-capital 2020-04-09T08:53:02-04:00 https://ir.scynexis.com/news/detail/204/scynexis-to-virtually-present-on-the-candida-auris-treatment-landscape-at-the-22nd-annual-superbugs-and-superdrugs-conference-2020 2020-03-26T08:00:05-04:00 https://ir.scynexis.com/news/detail/203/scynexis-reports-full-year-2019-financial-results-and-provides-company-update 2020-03-11T08:18:10-04:00 https://ir.scynexis.com/news/detail/202/scynexis-announces-preclinical-data-on-ibrexafungerp-and-azoles-against-aspergillus-presented-at-the-9th-advances-against-aspergillosis-and-mucormycosis-conference 2020-03-05T08:00:13-05:00 https://ir.scynexis.com/news/detail/201/scynexis-completes-patient-enrollment-ahead-of-schedule-in-the-second-pivotal-phase-3-study-vanish-306-of-oral-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vaginal-yeast-infection 2020-02-13T08:08:03-05:00 https://ir.scynexis.com/news/detail/200/scynexis-announces-positive-results-from-the-second-interim-analysis-of-ongoing-phase-3-furi-study-demonstrating-oral-ibrexafungerps-ability-to-treat-severe-fungal-infections-in-the-hospital-setting 2020-01-08T07:30:04-05:00 https://ir.scynexis.com/news/detail/199/scynexis-appoints-business-development-veteran-philippe-tinmouth-to-its-board-of-directors 2019-12-16T08:30:04-05:00 https://ir.scynexis.com/news/detail/198/scynexis-announces-closing-of-35-million-public-offering-of-common-stock-and-warrants 2019-12-12T12:46:44-05:00 https://ir.scynexis.com/news/detail/197/scynexis-announces-pricing-of-35-million-public-offering-of-common-stock-and-warrants 2019-12-10T06:22:53-05:00 https://ir.scynexis.com/news/detail/196/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants 2019-12-09T16:01:04-05:00 https://ir.scynexis.com/news/detail/195/scynexis-commends-the-cdc-for-the-recognition-of-candida-auris-as-a-new-urgent-threat-in-its-updated-report-on-antibiotic-resistance-threats-in-the-united-states 2019-11-14T08:30:09-05:00 https://ir.scynexis.com/news/detail/194/scynexis-reports-third-quarter-2019-financial-results-and-provides-company-update 2019-11-12T08:30:08-05:00 https://ir.scynexis.com/news/detail/193/scynexis-reports-positive-top-line-results-from-first-phase-3-registration-study-of-oral-ibrexafungerp-in-vulvovaginal-candidiasis-vanish-303 2019-11-07T08:00:19-05:00 https://ir.scynexis.com/news/detail/192/scynexis-announces-oral-presentation-of-data-from-ibrexafungerp-phase-2b-dove-study-at-the-3rd-isidog-congress 2019-10-31T08:30:08-04:00 https://ir.scynexis.com/news/detail/191/scynexis-expands-furi-protocol-to-a-broader-range-of-refractory-serious-fungal-infections-building-on-ibrexafungerps-positive-data-and-favorable-toxicology-profile-observed-to-date 2019-10-24T08:30:04-04:00 https://ir.scynexis.com/news/detail/190/scynexis-to-strengthen-its-balance-sheet-with-non-dilutive-funding-through-the-new-jersey-economic-development-authority-net-operating-loss-and-rd-tax-credits-program 2019-10-10T08:30:07-04:00 https://ir.scynexis.com/news/detail/189/scynexis-to-present-data-at-idweek-2019-and-the-9th-congress-on-trends-in-medical-mycology-timm-9-highlighting-scientific-and-clinical-evidence-of-ibrexafungerps-activity-against-resistant-fungal-pathogens-including-candida-auris 2019-10-02T08:30:05-04:00 https://ir.scynexis.com/news/detail/188/scynexis-completes-last-patientlast-visit-ahead-of-schedule-in-the-first-phase-3-study-vanish-303-of-oral-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc 2019-09-18T08:30:08-04:00 https://ir.scynexis.com/news/detail/187/scynexis-inc-to-participate-in-two-upcoming-investor-conferences 2019-09-04T07:00:12-04:00 https://ir.scynexis.com/news/detail/186/scynexis-reports-second-quarter-2019-financial-results-and-provides-company-update 2019-08-07T16:15:17-04:00 https://ir.scynexis.com/news/detail/185/scynexis-inc-to-present-at-the-39th-annual-canaccord-genuity-global-growth-conference 2019-08-06T16:53:51-04:00 https://ir.scynexis.com/news/detail/184/scynexis-announces-special-protocol-assessment-spa-agreement-with-fda-for-phase-3-study-evaluating-oral-ibrexafungerp-for-the-prevention-of-recurrent-vulvovaginal-candidiasis-vvc-candle-study 2019-07-24T08:00:38-04:00 https://ir.scynexis.com/news/detail/183/world-renowned-fungal-infection-expert-comments-on-oral-ibrexafungerp-data-presented-by-scynexis-at-asm-microbe-2019 2019-06-25T15:45:17-04:00 https://ir.scynexis.com/news/detail/182/scynexis-appoints-dr-nkechi-azie-as-vice-president-of-clinical-development 2019-06-14T08:30:03-04:00 https://ir.scynexis.com/news/detail/181/scynexis-to-present-data-at-asm-microbe-2019-demonstrating-the-broad-potential-utility-of-ibrexafungerp-for-the-treatment-and-prevention-of-multiple-severe-fungal-infections 2019-06-05T08:30:06-04:00 https://ir.scynexis.com/news/detail/180/scynexis-reports-completion-of-chronic-nonclinical-toxicology-studies-supporting-long-term-administration-of-ibrexafungerp 2019-05-30T08:30:06-04:00 https://ir.scynexis.com/news/detail/179/scynexis-reports-first-quarter-2019-financial-results-and-provides-company-update 2019-05-08T16:15:20-04:00 https://ir.scynexis.com/news/detail/178/scynexis-presents-data-at-acog-2019-further-supporting-a-future-nda-submission-of-oral-ibrexafungerp-for-vulvovaginal-candidiasis-vvc 2019-05-06T08:30:15-04:00 https://ir.scynexis.com/news/detail/177/scynexis-to-present-data-at-acog-2019-further-demonstrating-the-favorable-profile-of-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc 2019-05-02T16:50:15-04:00 https://ir.scynexis.com/news/detail/176/scynexis-to-discuss-eccmid-2019-clinical-data-including-successful-case-studies-in-candida-auris-and-other-difficult-to-treat-infections-on-conference-call 2019-04-15T08:30:06-04:00 https://ir.scynexis.com/news/detail/175/scynexis-commends-the-new-york-times-for-its-reporting-on-candida-auris-and-other-drug-resistant-pathogens 2019-04-08T08:15:03-04:00 https://ir.scynexis.com/news/detail/174/scynexiss-ibrexafungerp-shows-favorable-clinical-activity-in-resistant-fungal-infections-including-candida-auris-cases-from-the-cares-study-in-data-to-be-presented-at-the-29th-eccmid 2019-04-03T08:30:06-04:00 https://ir.scynexis.com/news/detail/173/scynexis-inc-to-present-at-upcoming-investor-conferences 2019-04-01T08:00:19-04:00 https://ir.scynexis.com/news/detail/172/scynexis-reports-full-year-2018-financial-results-and-provides-company-update 2019-03-14T16:39:26-04:00 https://ir.scynexis.com/news/detail/171/scynexis-is-retiring-existing-term-loan-through-a-lower-interest-and-longer-term-convertible-note 2019-03-07T09:34:57-05:00 https://ir.scynexis.com/news/detail/170/scynexis-to-present-pre-clinical-data-supporting-prophylactic-use-of-ibrexafungerp-at-superbugs-and-superdrugs-2019 2019-02-28T08:30:04-05:00 https://ir.scynexis.com/news/detail/169/scynexis-announces-positive-interim-results-from-phase-3-open-label-furi-study-showing-oral-ibrexafungerps-ability-to-treat-refractory-fungal-infections-and-to-provide-an-alternative-to-long-term-iv-therapies 2019-01-30T16:05:14-05:00 https://ir.scynexis.com/news/detail/168/scynexis-announces-appointment-of-industry-veteran-armando-anido-to-its-board-of-directors 2019-01-22T08:45:03-05:00 https://ir.scynexis.com/news/detail/167/scynexis-provides-year-end-update-and-outlines-plans-for-2019 2019-01-03T16:05:05-05:00 https://ir.scynexis.com/news/detail/166/scynexis-inc-to-present-at-upcoming-investor-conferences 2018-11-20T08:00:14-05:00 https://ir.scynexis.com/news/detail/165/scynexis-reports-third-quarter-2018-financial-results-and-provides-company-update 2018-11-13T09:05:05-05:00 https://ir.scynexis.com/news/detail/164/scynexis-announces-fda-agreement-with-company-proposed-phase-3-vulvovaginal-candidiasis-program-for-oral-ibrexafungerp 2018-10-23T09:00:16-04:00 https://ir.scynexis.com/news/detail/163/scynexis-inc-announces-first-patient-dosed-in-phase-3-open-label-study-evaluating-oral-ibrexafungerp-in-candida-auris-infections-cares 2018-10-15T09:26:32-04:00 https://ir.scynexis.com/news/detail/162/scynexis-supports-amr-challenge-and-fungal-disease-awareness-week 2018-10-01T09:25:02-04:00 https://ir.scynexis.com/news/detail/161/scynexis-to-present-an-overview-of-the-companys-pipeline-at-idweek-2018 2018-09-26T08:00:03-04:00 https://ir.scynexis.com/news/detail/160/scynexis-inc-to-present-at-upcoming-investor-conferences 2018-09-25T08:00:10-04:00 https://ir.scynexis.com/news/detail/159/scynexis-inc-presents-ibrexafungerp-data-at-the-2018-escmidasm-conference-on-drug-development 2018-09-04T08:00:08-04:00 https://ir.scynexis.com/news/detail/158/scynexis-inc-to-participate-in-upcoming-investor-conferences 2018-08-29T08:00:04-04:00 https://ir.scynexis.com/news/detail/157/scynexis-reports-second-quarter-2018-financial-results-and-provides-company-update 2018-08-09T16:15:10-04:00 https://ir.scynexis.com/news/detail/156/the-world-health-organization-recognizes-new-antifungal-class-by-granting-ibrexafungerp-to-scynexis-as-the-international-non-proprietary-name-for-scy-078 2018-07-18T08:05:02-04:00 https://ir.scynexis.com/news/detail/155/scynexis-reports-positive-results-from-phase-2b-dose-finding-study-of-oral-scy-078-in-vulvovaginal-candidiasis 2018-07-10T16:05:05-04:00 https://ir.scynexis.com/news/detail/154/scynexis-announces-the-presentation-of-scy-078-data-at-the-teratology-society-58th-annual-meeting 2018-06-27T08:03:12-04:00 https://ir.scynexis.com/news/detail/153/scynexis-to-present-scy-078-data-at-three-scientific-meetings-in-junejuly-2018 2018-06-14T08:05:13-04:00 https://ir.scynexis.com/news/detail/152/scynexis-presents-scy-078-data-at-asm-microbe-2018 2018-06-11T08:30:03-04:00 https://ir.scynexis.com/news/detail/151/scynexis-announces-the-publication-of-phase-1-study-results-for-scy-078-in-the-journal-of-clinical-pharmacology 2018-06-06T08:30:06-04:00 https://ir.scynexis.com/news/detail/150/scynexis-to-present-scy-078-data-at-asm-microbe-2018 2018-05-24T08:30:06-04:00 https://ir.scynexis.com/news/detail/149/scynexis-to-participate-in-a-panel-at-the-2018-bio-international-convention 2018-05-23T08:30:03-04:00 https://ir.scynexis.com/news/detail/148/scynexis-reports-first-quarter-2018-financial-results-and-provides-company-update 2018-05-08T16:20:03-04:00 https://ir.scynexis.com/news/detail/147/scynexiss-oral-scy-078-receives-fda-qidp-and-fast-track-designations-for-the-treatment-of-vvc-and-prevention-of-recurrent-vvc 2018-05-01T08:30:10-04:00 https://ir.scynexis.com/news/detail/146/scynexis-data-presentations-at-eccmid-2018-show-scy-078-potent-and-synergistic-antifungal-activity-against-aspergillus-and-pneumocystis 2018-04-23T08:00:15-04:00 https://ir.scynexis.com/news/detail/145/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid 2018-04-10T07:30:02-04:00 https://ir.scynexis.com/news/detail/144/scynexis-to-present-at-the-17th-annual-needham-healthcare-conference 2018-03-21T07:30:05-04:00 https://ir.scynexis.com/news/detail/143/scynexis-presents-data-at-superbugs-and-superdrugs-2018 2018-03-20T16:05:03-04:00 https://ir.scynexis.com/news/detail/142/scynexis-reports-full-year-2017-financial-results-and-provides-company-update 2018-03-13T16:25:04-04:00 https://ir.scynexis.com/news/detail/141/scynexis-to-present-at-the-30th-annual-roth-conference 2018-03-07T07:35:00-05:00 https://ir.scynexis.com/news/detail/140/scynexis-announces-pricing-of-30-0-million-public-offering-of-common-stock-and-warrants 2018-03-06T09:25:02-05:00 https://ir.scynexis.com/news/detail/139/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants 2018-03-05T16:02:29-05:00 https://ir.scynexis.com/news/detail/138/scynexis-presents-new-in-vivo-data-highlighting-the-potential-of-scy-078-used-in-combination-for-the-treatment-of-aspergillus-infections-at-aaa-2018 2018-02-01T08:30:20-05:00 https://ir.scynexis.com/news/detail/137/scynexis-provides-corporate-and-scy-078-pipeline-update 2018-01-04T16:05:03-05:00 https://ir.scynexis.com/news/detail/136/scynexis-to-participate-in-upcoming-investor-conferences 2017-11-28T08:00:14-05:00 https://ir.scynexis.com/news/detail/28/scynexis-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference 2017-11-22T08:00:04-05:00 https://ir.scynexis.com/news/detail/27/scynexis-appoints-scott-sukenick-as-general-counsel 2017-11-16T17:56:44-05:00 https://ir.scynexis.com/news/detail/26/scynexis-reports-third-quarter-2017-financial-results-and-provides-company-update 2017-11-07T16:20:17-05:00 https://ir.scynexis.com/news/detail/25/scynexis-presents-new-data-further-supporting-scy-078-as-a-potential-treatment-for-aspergillus-and-candida-infections-at-idweek-2017 2017-10-05T08:30:03-04:00 https://ir.scynexis.com/news/detail/24/scynexis-to-present-data-on-lead-antifungal-candidate-scy-078-at-idweek-2017 2017-09-27T08:30:03-04:00 https://ir.scynexis.com/news/detail/23/scynexis-to-present-at-upcoming-investor-conferences 2017-08-31T09:05:01-04:00 https://ir.scynexis.com/news/detail/22/think-fungus---scynexis-recognizes-fungal-disease-awareness-week-sponsored-by-the-centers-for-disease-control-and-prevention-cdc 2017-08-15T08:01:04-04:00 https://ir.scynexis.com/news/detail/21/scynexis-presents-new-data-supporting-oral-scy-078-for-the-clinical-treatment-of-vulvovaginal-candidiasis-infections-at-the-2017-idsog-annual-meeting 2017-08-14T08:00:39-04:00 https://ir.scynexis.com/news/detail/20/scynexis-reports-second-quarter-2017-financial-results-and-provides-company-update 2017-08-08T16:25:01-04:00 https://ir.scynexis.com/news/detail/19/scynexis-to-present-at-the-canaccord-genuity-growth-conference 2017-08-07T09:05:01-04:00 https://ir.scynexis.com/news/detail/18/scynexis-announces-initiation-of-dosing-in-phase-2-study-evaluating-oral-scy-078-in-vulvovaginal-candidiasis 2017-08-03T16:05:15-04:00 https://ir.scynexis.com/news/detail/17/new-study-further-demonstrates-in-vitro-activity-of-scynexis-lead-anti-infective-candidate-scy-078-against-drug-resistant-candida-fungal-strains 2017-06-15T08:30:16-04:00 https://ir.scynexis.com/news/detail/16/scynexis-inc-to-participate-in-the-2017-bio-international-convention 2017-06-13T09:05:02-04:00 https://ir.scynexis.com/news/detail/15/eight-presentations-at-asm-microbe-2017-further-highlight-the-strong-antifungal-effect-and-promising-safety-profile-of-lead-anti-infective-candidate-scy-078 2017-06-05T08:30:51-04:00 https://ir.scynexis.com/news/detail/14/eight-scy-078-data-presentations-at-asm-microbe-2017-confirm-potential-of-scynexis-lead-agent-to-combat-serious-and-life-threatening-fungal-infections 2017-05-24T09:05:04-04:00 https://ir.scynexis.com/news/detail/13/potent-in-vitro-activity-of-scynexis-scy-078-against-multidrug-resistant-fungal-pathogen-candida-auris-further-confirmed-in-an-in-vitro-study-conducted-by-the-centers-for-disease-control-and-prevention-cdc 2017-05-11T08:34:31-04:00 https://ir.scynexis.com/news/detail/12/scynexis-reports-first-quarter-2017-financial-results-and-provides-update-on-iv-formulation-development-status 2017-05-08T16:20:02-04:00 https://ir.scynexis.com/news/detail/11/eight-data-presentations-at-eccmid-showcase-the-broad-applicability-of-scynexis-lead-anti-infective-candidate-scy-078 2017-04-25T09:00:14-04:00 https://ir.scynexis.com/news/detail/10/scynexis-to-host-a-conference-call-to-discuss-lead-anti-infective-candidate-scy-078-data-presented-at-27th-eccmid 2017-04-21T09:00:05-04:00 https://ir.scynexis.com/news/detail/9/scynexis-to-present-scy-078-data-on-novel-lead-anti-infective-candidate-at-27th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid 2017-04-12T08:30:05-04:00 https://ir.scynexis.com/news/detail/8/scynexis-inc-to-present-at-the-16th-annual-needham-healthcare-conference 2017-03-29T09:05:02-04:00 https://ir.scynexis.com/news/detail/7/scynexis-reports-full-year-2016-financial-results-and-provides-company-update 2017-03-13T16:30:02-04:00 https://ir.scynexis.com/news/detail/6/scynexis-inc-to-present-at-the-29th-annual-roth-conference 2017-03-07T09:05:01-05:00 https://ir.scynexis.com/news/detail/5/scynexis-delays-initiation-of-new-clinical-studies-using-the-iv-formulation-of-scy-078-at-fdas-request 2017-03-02T16:05:02-05:00 https://ir.scynexis.com/news/detail/91/scynexis-inc-to-participate-in-upcoming-investor-conferences 2017-11-27T15:44:02-05:00 https://ir.scynexis.com/news/detail/90/scynexis-announces-appointment-of-industry-veteran-marion-mccourt-to-its-board-of-directors 2017-11-27T15:44:02-05:00 https://ir.scynexis.com/news/detail/89/scynexis-achieves-new-development-milestones-reinforcing-the-versatility-of-scy-078-in-treating-serious-fungal-infections 2017-11-27T15:44:01-05:00 https://ir.scynexis.com/news/detail/88/scynexis-inc-to-participate-in-the-guggenheim-securities-4th-annual-boston-healthcare-conference 2017-11-27T15:44:00-05:00 https://ir.scynexis.com/news/detail/87/scynexis-inc-reports-third-quarter-2016-financial-results-and-provides-company-update 2017-11-27T15:43:59-05:00 https://ir.scynexis.com/news/detail/86/scynexis-completes-two-additional-clinical-studies-further-supporting-the-favorable-safety-profile-of-scy-078 2017-11-27T15:43:58-05:00 https://ir.scynexis.com/news/detail/85/scynexis-announces-complete-results-from-two-phase-2-studies-of-oral-scy-078-in-patients-with-candida-spp-infections-and-closing-of-a-15-million-term-loan 2017-11-27T15:43:57-05:00 https://ir.scynexis.com/news/detail/84/scynexis-inc-to-present-at-the-ladenburg-thalmann-healthcare-conference 2017-11-27T15:43:57-05:00 https://ir.scynexis.com/news/detail/83/scynexis-inc-to-present-at-upcoming-investor-conferences 2017-11-27T15:43:56-05:00 https://ir.scynexis.com/news/detail/82/scynexis-inc-receives-orphan-drug-designation-for-scy-078-for-the-treatment-of-invasive-aspergillus-infections 2017-11-27T15:43:55-05:00 https://ir.scynexis.com/news/detail/81/scynexis-inc-reports-second-quarter-2016-financial-results-and-provides-company-update 2017-11-27T15:43:54-05:00 https://ir.scynexis.com/news/detail/80/scynexis-inc-to-present-at-the-canaccord-genuity-growth-conference 2017-11-27T15:43:53-05:00 https://ir.scynexis.com/news/detail/79/scynexis-announces-interim-results-from-phase-2-study-of-oral-scy-078-in-patients-with-invasive-candidiasis 2017-11-27T15:43:53-05:00 https://ir.scynexis.com/news/detail/78/scynexis-inc-announces-sale-of-cyclophilin-inhibitor-assets-to-cypralis-limited 2017-11-27T15:43:52-05:00 https://ir.scynexis.com/news/detail/77/scynexis-inc-to-present-at-cantor-fitzgeralds-2nd-annual-healthcare-conference 2017-11-27T15:43:51-05:00 https://ir.scynexis.com/news/detail/76/scynexis-announces-pricing-of-22-5-million-public-offering-of-common-stock-and-warrants 2017-11-27T15:43:50-05:00 https://ir.scynexis.com/news/detail/75/scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants 2017-11-27T15:43:50-05:00 https://ir.scynexis.com/news/detail/74/scynexis-inc-presents-new-clinical-and-non-clinical-data-confirming-the-potential-of-scy-078-as-a-novel-treatment-for-life-threatening-fungal-infections 2017-11-27T15:43:49-05:00 https://ir.scynexis.com/news/detail/73/scynexis-to-present-data-from-lead-antifungal-drug-candidate-scy-078-at-asm-microbe-2016 2017-11-27T15:43:48-05:00 https://ir.scynexis.com/news/detail/72/scynexis-inc-announces-positive-results-in-its-proof-of-concept-phase-2-study-of-scy-078-the-first-member-of-a-novel-class-of-glucan-synthase-inhibitors 2017-11-27T15:43:47-05:00 https://ir.scynexis.com/news/detail/71/scynexis-inc-receives-orphan-drug-designation-for-scy-078-for-the-treatment-of-invasive-candida-infections 2017-11-27T15:43:45-05:00 https://ir.scynexis.com/news/detail/70/scynexis-inc-reports-first-quarter-2016-financial-results-and-provides-company-update 2017-11-27T15:43:45-05:00 https://ir.scynexis.com/news/detail/69/scynexis-receives-designation-as-a-small-and-medium-enterprise-by-the-european-medicines-agency 2017-11-27T15:43:44-05:00 https://ir.scynexis.com/news/detail/68/scynexis-presents-data-supporting-the-activity-of-its-lead-antifungal-drug-candidate-scy-078-against-antifungal-resistant-candida-strains-at-the-13th-asm-conference-on-candida-and-candidiasis 2017-11-27T15:43:43-05:00 https://ir.scynexis.com/news/detail/67/scynexis-inc-to-present-at-the-15th-annual-needham-healthcare-conference 2017-11-27T15:43:43-05:00 https://ir.scynexis.com/news/detail/66/scynexis-to-present-data-from-lead-antifungal-drug-candidate-scy-078-at-13th-asm-conference-on-candida-and-candidiasis 2017-11-27T15:43:42-05:00 https://ir.scynexis.com/news/detail/65/scynexis-inc-reports-full-year-2015-financial-results-and-provides-company-update 2017-11-27T15:43:40-05:00 https://ir.scynexis.com/news/detail/64/scynexis-inc-to-present-at-the-cowen-and-company-36th-annual-health-care-conference 2017-11-27T15:43:40-05:00 https://ir.scynexis.com/news/detail/63/scynexis-inc-to-present-at-upcoming-investor-conferences 2017-11-27T15:43:39-05:00 https://ir.scynexis.com/news/detail/62/scynexis-inc-receives-fda-fast-track-and-qidp-designations-for-intravenous-formulation-of-scy-078-for-the-treatment-of-patients-with-invasive-fungal-infections 2017-11-27T15:43:38-05:00 https://ir.scynexis.com/news/detail/61/scynexis-inc-initiates-enrollment-of-the-phase-2-study-of-scy-078-in-vulvovaginal-candidiasis 2017-11-27T15:43:38-05:00 https://ir.scynexis.com/news/detail/60/scynexis-inc-reports-third-quarter-2015-financial-results-and-provides-company-update 2017-11-27T15:43:37-05:00 https://ir.scynexis.com/news/detail/59/scynexis-inc-announces-initiation-of-phase-1-clinical-trial-evaluating-intravenous-formulation-of-scy-078 2017-11-27T15:43:36-05:00 https://ir.scynexis.com/news/detail/58/scynexis-appoints-eric-francois-as-chief-financial-officer 2017-11-27T15:43:36-05:00 https://ir.scynexis.com/news/detail/57/scynexis-appoints-rajeshwar-motheram-as-vice-president-pharmaceutical-development 2017-11-27T15:43:35-05:00 https://ir.scynexis.com/news/detail/56/scynexis-inc-announces-board-of-directors-transitions 2017-11-27T15:43:34-05:00 https://ir.scynexis.com/news/detail/55/scynexis-presents-data-supporting-the-potential-clinical-utility-of-antifungal-drug-candidate-at-icaacicc-2015 2017-11-27T15:43:34-05:00 https://ir.scynexis.com/news/detail/54/scynexis-to-present-data-at-icaacicc-2015-for-novel-antifungal-drug-candidate 2017-11-27T15:43:33-05:00 https://ir.scynexis.com/news/detail/53/scynexis-inc-reports-second-quarter-2015-financial-results 2017-11-27T15:43:32-05:00 https://ir.scynexis.com/news/detail/52/scynexis-inc-to-present-at-35th-canaccord-genuity-annual-growth-conference 2017-11-27T15:43:32-05:00 https://ir.scynexis.com/news/detail/51/scynexis-inc-to-focus-on-scy-078-development 2017-11-27T15:43:31-05:00 https://ir.scynexis.com/news/detail/50/scynexis-inc-to-present-at-10th-annual-jmp-securities-life-sciences-conference 2017-11-27T15:43:30-05:00 https://ir.scynexis.com/news/detail/49/scynexis-inc-announces-changes-to-board-of-directors 2017-11-27T15:43:30-05:00 https://ir.scynexis.com/news/detail/48/scynexis-inc-announces-new-employment-inducement-grant 2017-11-27T15:43:29-05:00 https://ir.scynexis.com/news/detail/47/scynexis-inc-to-present-at-jefferies-2015-healthcare-conference 2017-11-27T15:43:28-05:00 https://ir.scynexis.com/news/detail/46/scynexis-inc-reports-first-quarter-2015-financial-results 2017-11-27T15:43:27-05:00 https://ir.scynexis.com/news/detail/45/scynexis-appoints-david-angulo-m-d-as-chief-medical-officer 2017-11-27T15:43:27-05:00 https://ir.scynexis.com/news/detail/44/scynexis-announces-pricing-of-public-offering-of-common-stock 2017-11-27T15:43:26-05:00 https://ir.scynexis.com/news/detail/43/scynexis-announces-launch-of-public-offering-of-common-stock 2017-11-27T15:43:25-05:00 https://ir.scynexis.com/news/detail/41/scynexis-inc-reports-full-year-2014-financial-results 2017-11-27T15:43:23-05:00 https://ir.scynexis.com/news/detail/42/scynexis-inc-to-present-at-jefferies-2015-antibiotic-summit 2017-11-27T15:43:25-05:00 https://ir.scynexis.com/news/detail/40/scynexis-inc-appoints-steven-c-gilman-ph-d-to-board-of-directors 2017-11-27T15:43:23-05:00 https://ir.scynexis.com/news/detail/39/scynexis-inc-to-present-at-rbc-capital-markets-2015-healthcare-conference 2017-11-27T15:43:22-05:00 https://ir.scynexis.com/news/detail/38/scynexis-names-marco-taglietti-m-d-chief-executive-officer 2017-11-27T15:43:21-05:00 https://ir.scynexis.com/news/detail/37/scynexis-inc-receives-fda-fast-track-designation-for-oral-formulation-of-scy-078-for-the-treatment-of-patients-with-invasive-fungal-infections 2017-11-27T15:43:21-05:00 https://ir.scynexis.com/news/detail/36/scynexis-inc-announces-appointment-of-two-seasoned-industry-professionals-to-its-board-of-directors 2017-11-27T15:43:20-05:00 https://ir.scynexis.com/news/detail/35/scynexis-inc-reports-third-quarter-2014-financial-results 2017-11-27T15:43:20-05:00 https://ir.scynexis.com/news/detail/34/scynexis-inc-enters-into-worldwide-agreement-with-waterstone-pharmaceutical-for-the-development-and-commercialization-of-scy-635-for-viral-diseases 2017-11-27T15:43:19-05:00 https://ir.scynexis.com/news/detail/33/scynexis-inc-reports-second-quarter-2014-financial-results 2017-11-27T15:43:18-05:00 https://ir.scynexis.com/news/detail/32/scynexis-inc-to-present-at-canaccord-genuity-growth-conference-2014 2017-11-27T15:43:18-05:00 https://ir.scynexis.com/news/detail/30/scynexis-inc-to-present-at-jmp-securities-healthcare-conference 2017-11-27T15:43:16-05:00 https://ir.scynexis.com/news/detail/31/scynexis-provides-update-on-corporate-progress-and-first-quarter-2014-financial-results 2017-11-27T15:43:17-05:00 https://ir.scynexis.com/news/detail/29/scynexis-announces-pricing-of-initial-public-offering 2017-12-15T17:54:35-05:00 https://ir.scynexis.com/news/detail/135/scynexis-announces-launch-of-initial-public-offering-of-common-stock 2017-12-15T17:54:41-05:00 https://ir.scynexis.com/news/detail/134/scynexis-appoints-carole-sable-md-as-chief-medical-officer 2017-12-15T17:54:41-05:00 https://ir.scynexis.com/news/detail/133/scynexis-receives-qualified-infectious-disease-product-qidp-designation-from-the-fda-for-antifungal-agent-scy-078-for-oral-use 2017-12-15T17:54:41-05:00 https://ir.scynexis.com/news/detail/132/scynexis-appoints-vivian-doelling-as-vice-president-of-animal-health 2017-11-27T15:46:28-05:00 https://ir.scynexis.com/news/detail/131/scynexis-signs-deal-with-r-pharm-to-develop-and-market-novel-antifungal-compound-in-russia-and-other-markets 2017-11-27T15:46:28-05:00 https://ir.scynexis.com/news/detail/130/scynexis-gains-worldwide-rights-to-novel-antifungal-compound 2017-11-27T15:46:27-05:00 https://ir.scynexis.com/news/detail/129/scynexis-presents-scy-635-data-on-hcv-at-international-liver-congress 2017-12-15T17:54:40-05:00 https://ir.scynexis.com/news/detail/128/scynexis-and-immune-design-collaborate-on-innovative-process-for-vaccine-production-technology 2017-11-27T15:46:26-05:00 https://ir.scynexis.com/news/detail/127/scynexis-oral-scy-635-shows-potential-as-an-immune-acting-antiviral-to-augment-current-hcv-treatments 2017-12-15T17:54:40-05:00 https://ir.scynexis.com/news/detail/126/scynexis-announces-exclusive-licensing-deal-for-the-treatment-of-canine-dry-eye 2017-12-15T17:54:39-05:00 https://ir.scynexis.com/news/detail/125/scynexis-to-present-on-screening-technology-used-in-anti-malarial-research-at-acs-national-meeting 2017-11-27T15:46:25-05:00 https://ir.scynexis.com/news/detail/124/abide-therapeutics-and-scynexis-collaborate-in-finding-novel-anti-viral-and-anti-parasitic-agents 2017-11-27T15:46:25-05:00 https://ir.scynexis.com/news/detail/123/morria-biopharmaceuticals-plc-selects-scynexis-to-support-cmc-activities-for-mrx-4-a-novel-anti-inflammatory-drug-for-allergic-rhinitis 2017-11-27T15:46:24-05:00 https://ir.scynexis.com/news/detail/122/mmv-and-scynexis-offer-400-active-compounds-for-neglected-disease-drug-research-at-no-cost 2017-11-27T15:46:24-05:00 https://ir.scynexis.com/news/detail/121/innovative-vector-control-consortium-announces-discovery-project-with-scynexis 2017-11-27T15:46:24-05:00 https://ir.scynexis.com/news/detail/120/scynexis-and-tb-alliance-sign-heos-software-agreement 2017-11-27T15:46:23-05:00 https://ir.scynexis.com/news/detail/119/dr-dennis-schmatz-joins-scynexis-as-strategic-advisor 2017-11-27T15:46:23-05:00 https://ir.scynexis.com/news/detail/118/scynexis-receives-four-grants-under-federal-therapeutic-discovery-project-program 2017-12-15T17:54:39-05:00 https://ir.scynexis.com/news/detail/117/scynexis-introduces-application-for-mobile-access-to-heos-information-system 2017-11-27T15:46:22-05:00 https://ir.scynexis.com/news/detail/116/scynexis-receives-merial-research-collaboration-milestone-payment 2017-11-27T15:46:21-05:00 https://ir.scynexis.com/news/detail/115/scynexis-announces-presentations-of-data-from-anti-fungal-drug-candidate-at-the-50th-icaac-meeting 2017-11-27T15:46:21-05:00 https://ir.scynexis.com/news/detail/114/scynexis-and-trevena-announce-strategic-collaboration-to-enhance-discovery-of-biased-gpcr-ligands 2017-11-27T15:46:21-05:00 https://ir.scynexis.com/news/detail/113/scynexis-presents-in-vitro-toxicity-study-suggesting-that-scy-635-is-unique-in-the-cyclophilin-inhibitor-class 2017-12-15T17:54:39-05:00 https://ir.scynexis.com/news/detail/112/scynexis-scy-635-demonstrates-impressive-barrier-to-resistance-in-hcv-treatment 2017-12-15T17:54:38-05:00 https://ir.scynexis.com/news/detail/111/scynexis-announces-acceptance-of-abstracts-related-to-its-hepatitis-c-clinical-candidate-scy-635-for-presentation-at-45th-annual-meeting-of-the-european-association-for-the-study-of-the-liver 2017-12-15T17:54:38-05:00 https://ir.scynexis.com/news/detail/110/scynexis-to-present-at-the-canaccord-adams-hepatitis-c-conference 2017-12-15T17:54:38-05:00 https://ir.scynexis.com/news/detail/109/scynexis-inc-receives-milestone-payment-from-collaboration-with-merck-co-inc 2017-11-27T15:46:18-05:00 https://ir.scynexis.com/news/detail/108/scynexis-cgmp-facilities-audited-by-fda----no-form-483-observations-issued 2017-11-27T15:46:18-05:00 https://ir.scynexis.com/news/detail/107/scynexis-receives-merial-research-collaboration-milestone-payment 2017-12-15T17:54:37-05:00 https://ir.scynexis.com/news/detail/106/scynexis-scy-635-demonstrates-positive-antiviral-activity-in-combination-with-approved-and-investigational-anti-hcv-agents 2017-12-15T17:54:37-05:00 https://ir.scynexis.com/news/detail/105/scynexis-to-present-hcv-data-on-novel-cyclophilin-inhibitor-scy-635-at-aasld-annual-meeting 2017-12-15T17:54:36-05:00 https://ir.scynexis.com/news/detail/104/scynexis-receives-milestone-payment-in-oncology-collaboration-with-merck-co-inc 2017-12-15T17:54:36-05:00 https://ir.scynexis.com/news/detail/103/scynexis-and-medicines-for-malaria-venture-sign-heosr-agreement 2017-12-15T17:54:36-05:00 https://ir.scynexis.com/news/detail/102/first-candidate-from-scynexis-novel-cyclophilin-inhibitor-platform-scy-635-establishes-proof-of-concept-in-hcv-infected-adults 2017-12-15T17:54:35-05:00 https://ir.scynexis.com/news/detail/101/scynexis-and-dndi-extend-collaboration-to-identify-drug-candidates-to-treat-sleeping-sickness 2017-11-27T15:46:14-05:00 https://ir.scynexis.com/news/detail/100/scynexis-to-present-preclinical-hcv-data-on-novel-cyclophillin-inhibitor-scy-635-at-aasld-annual-meeting 2017-11-27T15:46:14-05:00 https://ir.scynexis.com/news/detail/99/media-advisory---public-briefing-uniting-the-global-research-community-against-neglected-diseases 2017-11-27T15:46:14-05:00 https://ir.scynexis.com/news/detail/98/scynexis-convenes-renowned-scientists-for-symposium-on-the-therapeutic-promise-of-cyclophilin-inhibitors 2017-11-27T15:46:13-05:00 https://ir.scynexis.com/news/detail/97/scynexis-inc-completes-13-5-million-financing 2017-11-27T15:46:13-05:00 https://ir.scynexis.com/news/detail/96/scynexis-to-present-at-the-jpmorgan-healthcare-conference-on-january-8-2008 2017-11-27T15:46:13-05:00 https://ir.scynexis.com/news/detail/95/scynexis-receives-merial-research-collaboration-milestone-payment 2017-11-27T15:46:12-05:00 https://ir.scynexis.com/news/detail/94/scynexis-and-dndi-enter-landmark-multi-year-agreement-to-identify-drug-candidates-to-treat-sleeping-sickness 2017-11-27T15:46:12-05:00 https://ir.scynexis.com/news/detail/93/merial-scynexis-research-collaboration-expanded 2017-11-27T15:46:11-05:00 https://ir.scynexis.com/news/detail/92/scynexis-inc-receives-preclinical-milestone-payment-in-collaboration-with-merck 2017-11-27T15:46:11-05:00 https://ir.scynexis.com/events-presentations/detail/20260911-12th-cantor-global-healthcare-conference 2026-09-17T13:50:56-04:00 https://ir.scynexis.com/events-presentations/detail/20260625-2026-annual-meeting-of-stockholders 2026-09-17T13:50:56-04:00 https://ir.scynexis.com/events-presentations/detail/20260519-special-meeting-of-stockholders 2026-09-17T13:50:56-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001178253-26-000037/scyx-20260925.htm 2026-09-28T16:02:41-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001193125-26-397873/ownership.html 2026-09-22T16:03:14-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001193125-26-397869/ownership.html 2026-09-22T16:01:42-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001178253-26-000035/scyx-20260918.htm 2026-09-22T08:06:21-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001790246-26-000005/ownership.html 2026-09-11T16:03:44-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001790246-26-000004/ownership.html 2026-09-11T16:01:39-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001178253-26-000031/scyx-20260909.htm 2026-09-10T08:06:09-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001649553-26-000108/primary_doc.html 2026-08-14T14:45:29-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001172661-26-003532/primary_doc.html 2026-08-14T09:34:00-04:00 https://ir.scynexis.com/financials/sec-filings/content/0000919574-26-004987/primary_doc.html 2026-08-12T12:10:03-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001178253-26-000029/scyx-20260810.htm 2026-08-10T16:11:48-04:00 https://ir.scynexis.com/financials/sec-filings/content/0001178253-26-000027/scyx-20260630.htm 2026-08-10T16:03:00-04:00 https://ir.scynexis.com/disclaimer https://ir.scynexis.com/sitemap